Costs and effects of prenatal screening methods for down syndrome and neural tube defects

Community Genetics

Volumn 11, Issue 6, 2008, Pages 359-367

  Hoogendoorn, Mirjam ^a,b   Evers, Silvia M A A ^a   Schielen, Peter C J I ^b   Van Genugten, Marianne L L ^b,c   De Wit, G Ardine ^b   Ament, André J H A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Medtronic Nederland BV   (Netherlands)

Author keywords

Cost effectiveness; Down syndrome; Neural tube defects; Prenatal screening

Indexed keywords

ADULT; AMNIOCENTESIS; ARTICLE; BLOOD ANALYSIS; CHORION VILLUS SAMPLING; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC RISK; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; METHODOLOGY; NEURAL TUBE DEFECT; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY;

ABORTION, SPONTANEOUS; ADULT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOWN SYNDROME; FEMALE; GENETIC SCREENING; HUMANS; MATERNAL AGE; MODELS, ECONOMIC; NEURAL TUBE DEFECTS; PREGNANCY; PRENATAL DIAGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 49449118324     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000133308     Document Type: Article

References (24)

1. Morris JK, Mutton DE, Alberman E: Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2-6.
2. Statistics Netherlands: Live-born infants: key figures of fertility per region (in Dutch). www.cbs.nl.
3. Anthony S, Kateman H, Dorrepaal CA, Buitendijk SE: Congenital disorders in The Netherlands 1996-2000 (in Dutch). Leiden, TNO, 2003.
4. Alfirevic Z, Sundberg K, Brigham S: Amniocentesis and chorionic villus sampling for prenatal diagnosis (review). Cochrane Database Syst Rev 2003;3:CD003252.
5. Caughey AB, Kuppermann M, Norton ME, Washington AE: Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol 2002;187:1239-1245.
6. Cusick W, Buchanan P, Hallahan W, Krantz DA, Larsen JW, Macri JN: Combined firsttrimester versus second-trimester serum screening for Down's syndrome: a cost analysis. Am J Obstet Gynecol 2003;188:745-751.
7. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M, Van der Meulen JHP: Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 2001;323:423.
8. Harris AH: The cost effectiveness of prenatal screening for trisomy 21. Int J Technol Assess Health Care 2004;20:464-468.
9. Working Group Prenatal Diagnostics: Annual Report of Working Group Prenatal Diagnostics (in Dutch). Amsterdam, Nederlandse Vereniging voor Obstetrie en Gynaecologie, Vereniging Klinische Genetica Nederland, 2001.
10. Cuckle H, Arbuzova S: Multi-marker maternal serum screening for chromosomal abnormalities; in Milunsky A (ed): Genetic Disorders and the Fetus. Diagnosis, Prevention and Treatment. Baltimore, Johns Hopkins University Press, 2004.
11. Boyd PA, Wellesley DG, De Walle HEK, Tenconi R, Garcia-Minaur S, Zandwijken GRJ, Stoll C, Clementi M: Evaluation of the prenatal diagnosis of neural tube defects by fetal ultrasonographic examination in different centres across Europe. J Med Screen 2000;7:169-174.
12. Vos JMI, Offringa M, Bilardo CM, Lijmer JG, Barth PG: Sensitive and specific screening for detection of spina bifida by echography in the second trimester; systematic review and meta-analysis (in Dutch). Ned Tijdschr Geneeskd 2000;144:1736-1741.
13. CTG (Health Care Tariffs Board of The Netherlands): Supplement to tariff list for health care institutions 2003 (in Dutch). www.ctg-zaio.nl.
14. Oostenbrink JB, Koopmanschap MA, Rutten FFH: Methods and Guideline Prices for Economic Evaluations in Health Care (in Dutch). Amstelveen, CVZ (Health Care Insurance Board), 2000.
15. Prismant 2003: Other obstetric surgery (in Dutch). www.prismant.nl.
16. Liu DTY, Jeavons B, Preston C, Pearson D: A prospective study of spontaneous miscarriage in ultrasonically normal pregnancies and relevance to chorion villus sampling. Prenat Diagn 1987;7:223-227.
17. Spencer K: What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 2001;21:788-789.
18. Kriek R, Korenromp MJ, Hagenaars AM, Christiaens GCML, Bruinse HW: Screening for fetal neural tube defects. Alfa-fetoprotein concentration in maternal serum. Med Contact 1994;49:321-324.
19. Wald NJ, Cuckle H: Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet 1977;i:1323-1332.
20. Wald NJ, Cuckle HS, Boreham J, Brett R: Antenatal screening in Oxford for fetal neural tube defects. Br J Obstet Gynaecol 1979;86:91-100.
21. Wald NJ, Kennard A, Hackshaw A, McGuire A: Antenatal screening for Down's syndrome. Health Technol Assess 1998;2:1-112.
22. Spencer K: Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review. Br J Obstet Gynaecol 1999;106:1287-1293.
23. Health Council of The Netherlands: Prenatal screening: Down's syndrome, neural tube defects, routine ultrasonography. The Hague, Health Council of The Netherlands, 2001, Publ No 2001/11. www.gezondheidsraad.nl.
24. Cunningham GC, Tompkinson DG: Cost and effectiveness of the California triple marker prenatal screening program. Genet Med 1999;1:199-206.